Cannabis Involvement and Demand in Frequent Concentrate Users Versus Predominantly Flower Users.
Journal
Journal of studies on alcohol and drugs
ISSN: 1938-4114
Titre abrégé: J Stud Alcohol Drugs
Pays: United States
ID NLM: 101295847
Informations de publication
Date de publication:
03 2023
03 2023
Historique:
pmc-release:
01
03
2024
medline:
5
5
2023
pubmed:
28
3
2023
entrez:
27
3
2023
Statut:
ppublish
Résumé
Cannabis concentrate products contain more of the intoxicating cannabinoid, tetrahydrocannabinol, than flower products and, thus, may produce greater harm. Indeed, concentrate use is associated with greater cannabis dependence and problems (e.g., anxiety) than flower use. Given this, continued examination of concentrate versus flower use differences on associations with various cannabis measures may be useful. These measures include behavioral economic demand for cannabis (i.e., its subjective reinforcing value), use frequency, and dependence. In the present study of 480 cannabis users, those who were frequent concentrate users ( Two previously observed latent factors emerged, based on confirmatory factor analysis: Findings continue to indicate that the demand metrics, although distinct, can be parsimoniously condensed into two factors. In addition, method of administration (i.e., concentrate vs. flower use) may affect how demand for cannabis relates to frequency of use. Associations were notably stronger with frequency relative to dependence.
Identifiants
pubmed: 36971716
doi: 10.15288/jsad.22-00066
pmc: PMC10171257
doi:
Substances chimiques
Dronabinol
7J8897W37S
Cannabinoids
0
Hallucinogens
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
214-221Subventions
Organisme : NIDA NIH HHS
ID : R01 DA039707
Pays : United States
Déclaration de conflit d'intérêts
Meenu Minhas is currently an employee of Aurora Cannabis Inc., a Canadian Licensed Producer of Cannabis, but was not associated with the company at the time of her involvement with this study.
Références
Addict Behav Rep. 2018 Aug 17;8:102-106
pubmed: 30167450
Psychopharmacology (Berl). 2017 Aug;234(16):2421-2429
pubmed: 28508921
Neurotherapeutics. 2020 Jan;17(1):87-99
pubmed: 31916237
Brain Behav. 2020 Jan;10(1):e01486
pubmed: 31793226
Exp Clin Psychopharmacol. 2006 May;14(2):219-27
pubmed: 16756426
Addict Behav. 2012 Nov;37(11):1257-63
pubmed: 22727784
Exp Clin Psychopharmacol. 1999 Nov;7(4):412-26
pubmed: 10609976
J Stud Alcohol Drugs. 2021 May;82(3):351-361
pubmed: 34100703
Behav Res Ther. 2019 Apr;115:111-120
pubmed: 30497655
Exp Clin Psychopharmacol. 2008 Feb;16(1):57-65
pubmed: 18266552
Addiction. 2019 Nov;114(11):1926-1940
pubmed: 31313403
Complement Ther Med. 2021 Jan;56:102619
pubmed: 33227352
JAMA Psychiatry. 2020 Aug 1;77(8):787-796
pubmed: 32520316
Drug Alcohol Depend. 2007 Jul 10;89(2-3):107-15
pubmed: 17254719
J Consult Clin Psychol. 2000 Oct;68(5):898-908
pubmed: 11068976
Exp Clin Psychopharmacol. 2015 Oct;23(5):377-86
pubmed: 26147181
Exp Clin Psychopharmacol. 2022 Oct;30(5):584-592
pubmed: 34096758
Exp Clin Psychopharmacol. 2014 Jun;22(3):198-210
pubmed: 24749779
Drug Alcohol Depend. 2017 Sep 1;178:32-38
pubmed: 28624604
Drug Alcohol Depend. 2015 Jul 1;152:32-8
pubmed: 26002377
Addict Biol. 2022 Jan;27(1):e13092
pubmed: 34467598
Psychopharmacology (Berl). 2009 Mar;203(1):33-40
pubmed: 18925387
Biol Psychiatry. 2016 Apr 1;79(7):613-9
pubmed: 26903403
Exp Clin Psychopharmacol. 2015 Dec;23(6):504-12
pubmed: 26280591
Addiction. 2021 Oct;116(10):2635-2650
pubmed: 33338263